Application Detail
Description of Medical Service
Testing of tumour tissue by a pathologist, for patients with locally advanced or metastatic Cholangiocarcinoma, to detect IDH1 mutations. Confirmation of the disease will be required to determine eligibility for treatment with TibsovoŽ (ivosidenib), which is seeking PBS listing through a codependent submission.Description of Medical Condition
Cholangiocarcinoma is a type of cancer that encompasses all tumours originating from the epithelium of the bile duct. Bile ducts are a group of thin tubes that carry bile (a digestive fluid) from the liver and gallbladder into the intestines.Reason for Application
New MBS itemMedical Service Type
Investigative technologyPrevious Application Number/s
Not ApplicableAssociated Documentation
Application Summary and PICO Set
Application Summary (PDF 401 KB)Application Summary (Word 27 KB)
PICO Set (PDF 834 KB)
PICO Set (Word 300 KB)
Consultation Survey
Consultation Survey (PDF 654 KB)Consultation Survey (Word 27 KB)
PASC Consultation
Consultation closed
MSAC Consultation
MSAC consultation input must be received by no later than Friday, 14 June 2024 for it to be considered by MSAC at its August 2024 meeting.
For further information please refer to PASC, ESC, MSAC Key Dates
For further information on the consultation process please refer to MSAC Consultation Process
PICO Confirmation
PICO Confirmation (Word 728 KB)PICO Confirmation (PDF 973 KB)
Assessment Report
-Public Summary Document
-Meetings for this Application
PASC
10-11 August 2023ESC
13-14 June 2024MSAC
1-2 August 202428-29 November 2024